Edition:
United States

Omnicell Inc (OMCL.OQ)

OMCL.OQ on NASDAQ Stock Exchange Global Select Market

49.90USD
3:59pm EST
Change (% chg)

$-0.10 (-0.20%)
Prev Close
$50.00
Open
$49.95
Day's High
$50.65
Day's Low
$49.65
Volume
75,100
Avg. Vol
76,981
52-wk High
$55.40
52-wk Low
$31.90

Latest Key Developments (Source: Significant Developments)

Omnicell enters distribution agreement for sale of up to $125 mln maximum offering price of common stock
Friday, 3 Nov 2017 05:28pm EDT 

Nov 3 (Reuters) - Omnicell Inc :Omnicell says entered distribution agreement for sale of up to $125 million maximum offering price of common stock, par value $0.001/share ‍​- SEC filing.  Full Article

Omnicell reports Q3 GAAP earnings per share $0.16
Thursday, 26 Oct 2017 04:26pm EDT 

Oct 26 (Reuters) - Omnicell Inc :Omnicell achieves record revenue in the third quarter 2017.Q3 non-GAAP earnings per share $0.42.Q3 GAAP earnings per share $0.16.Q3 earnings per share view $0.42 -- Thomson Reuters I/B/E/S.Q3 revenue $187.1 million versus I/B/E/S view $186.7 million.Omnicell Inc - ‍for 2018 onwards, company expects organic growth to be in long term 8 pct-12 pct range​.Sees Q4 2017 non-GAAP earnings per share $0.49 to $0.55.Omnicell Inc - ‍expects both GAAP and non-GAAP revenue to be between $201 million and $207 million for Q4​.Omnicell Inc - ‍preliminary view of product bookings growth for 2018 is at high end and potentially above 8 pct-12 pct range​.Omnicell Inc - sees ‍for Q4 of 2017 both GAAP and non-GAAP revenue to be between $201 million and $207 million​.Omnicell Inc sees ‍8 pct-12 pct organic revenue growth over the long term​.Omnicell Inc - sees non-GAAP operating margin to be 15 pct over the ‍long term ​.Omnicell Inc sees ‍5 pct inorganic revenue growth on average over long term​.Q4 earnings per share view $0.52, revenue view $209.1 million -- Thomson Reuters I/B/E/S.  Full Article

Omnicell Q2 non-gaap earnings per share $0.31
Thursday, 27 Jul 2017 04:01pm EDT 

July 27 (Reuters) - Omnicell Inc ::Omnicell achieves record revenue in the second quarter 2017.Q2 non-gaap earnings per share $0.31.Q2 gaap earnings per share $0.02.Q2 earnings per share view $0.23 -- Thomson Reuters I/B/E/S.Q2 revenue $181.2 million versus I/B/E/S view $174.3 million.Omnicell Inc - for q3 of 2017, company expects both gaap and non-gaap revenue to be between $188 million and $194 million.Omnicell Inc - for year 2017, company expects product bookings to be between $570 million and $590 million.Sees q3 non-gaap earnings to be between $0.38 and $0.45 per share..Omnicell - company expects both gaap and non-gaap revenue to be between $720 million and $740 million for 2017.Sees non-gaap earnings to be between $1.22 and $1.34 per share for 2017.Q3 earnings per share view $0.45, revenue view $197.4 million -- Thomson Reuters I/B/E/S.Fy2017 earnings per share view $1.28, revenue view $729.6 million -- Thomson Reuters I/B/E/S.  Full Article

Omnicell adds to product offerings in Canada through agreement with McKesson Canada
Tuesday, 9 May 2017 08:00am EDT 

May 9 (Reuters) - Omnicell Inc : :Omnicell - agreement with Mckesson Canada under which direct sales of co's former aesynt products will transition from Mckesson Canada back to Omnicell.  Full Article

Omnicell announces Q1 GAAP loss per share $0.29
Thursday, 4 May 2017 08:00am EDT 

May 4 (Reuters) - Omnicell Inc : :Q2 earnings per share view $0.31, revenue view $180.8 million -- Thomson Reuters I/B/E/S.Omnicell announces first quarter 2017 results.Sees Q2 2017 non-gaap earnings per share $0.21 to $0.27.Q1 non-GAAP earnings per share $0.06.Q1 GAAP loss per share $0.29.Sees q2 2017 revenue $172 million to $178 million.Q1 earnings per share view $0.02 -- Thomson Reuters I/B/E/S.Q1 revenue $150.9 million versus I/B/E/S view $152.4 million.Sees FY 2017 non GAAP revenue $720 million to $740 million.Sees FY 2017 non-GAAP earnings per share $1.22 to $1.34.FY2017 earnings per share view $1.36, revenue view $748.1 million -- Thomson Reuters I/B/E/S.  Full Article

Omnicell acquires InPharmics
Wednesday, 19 Apr 2017 08:00am EDT 

April 19 (Reuters) - Omnicell Inc ::Omnicell acquires InPharmics.Omnicell Inc - financial details on acquisition are not being disclosed at this time.Omnicell Inc says expects transaction will be immaterial.Omnicell Inc says transaction does not expect it to impact Omnicell's previously communicated 2017 financial guidance.  Full Article

Omnicell says authorized stock repurchase program of up to $50 mln of co's stock
Friday, 5 Aug 2016 04:06pm EDT 

Omnicell Inc : 2016 repurchase program is in addition to stock repurchase program approved by board on november 4, 2014 .Authorized a stock repurchase program providing for repurchase of up to $50 million of company's common stock.  Full Article

Omnicell Inc gives Q2 2016 guidance
Thursday, 28 Apr 2016 04:01pm EDT 

Omnicell Inc:For Q2 2016, the company expects Non-GAAP revenue to be between $168 million and $175 million and Non-GAAP EPS to be between $0.30 and $0.34 per share.  Full Article

Omnicell Inc gives FY, Q1 2016 guidance
Thursday, 4 Feb 2016 04:01pm EST 

Omnicell Inc:Says for FY 2016, project product bookings to be between $540 and $560 million, revenue to be between $695 and $715 million.expect FY 2016 non-GAAP earnings to be between $1.50 and $1.60 per share, and non-GAAP operating margins to be approximately 12.7%.For FY 2016 expected non-GAAP results include approximately $10 million of integration expenses, primarily related to our acquisition of Aesynt, and about $6 mln of interest expense related to the loan facility used to finance the Aesynt acquisition.Says for Q1 2016, co expect revenue to be between $165 and $170 million and expected Non-GAAP EPS to be between $0.25 and $0.28 per share.  Full Article

BRIEF-Omnicell files for potential mixed shelf size undisclosed‍​‍​

* Omnicell files for potential mixed shelf; size undisclosed - SEC Filing ‍​‍​ Source text: http://bit.ly/2hatRZ4 Further company coverage: